Trial Profile
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Abexinostat (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FORERUNNER
- Sponsors Xynomic Pharmaceuticals
- 22 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 22 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 18 Aug 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.